Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 23, 2017
What is the competitive landscape for ABBVIE INC, and what generic alternatives to ABBVIE INC drugs are available?
ABBVIE INC has eight approved drugs.| International Patents: | 700 |
| US Patents: | 35 |
| Tradenames: | 8 |
| Ingredients: | 8 |
| NDAs: | 8 |
| Drug Master File Entries: (click here to view) | 17 |
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-001 | Sep 4, 2001 | ► Subscribe | ► Subscribe | ||||||||
Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | ► Subscribe | ► Subscribe | ||||||||
Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | ► Subscribe | ► Subscribe | ||||||||
Abbvie Inc | TRICOR | fenofibrate | TABLET;ORAL | 021203-003 | Sep 4, 2001 | ► Subscribe | ► Subscribe | ||||||||
Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir | TABLET, TABLET;ORAL | 206619-001 | Dec 19, 2014 | ► Subscribe | ► Subscribe | ||||||||
Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | ► Subscribe | ► Subscribe | ||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
ritonavir | Capsules | 100 mg | NORVIR | 10/31/2012 |
ritonavir | Tablets | 100 mg | NORVIR | 12/21/2010 |
fenofibrate | Tablets | 48 mg | TRICOR | 7/1/2008 |
fenofibrate | Tablets | 145 mg | TRICOR | 10/19/2007 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,183,416 | Polymorph of a pharmaceutical | ► Subscribe | |||||||||||||
| 8,332,661 | Method and apparatus for prevention of tampering, unauthorized use, and unauthorized extraction of information from microdevices | ► Subscribe | |||||||||||||
| 8,309,613 | Solid pharmaceutical dosage form | ► Subscribe | |||||||||||||
| 6,596,317 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it | ► Subscribe | |||||||||||||
| 8,377,952 | Solid pharmaceutical dosage formulation | ► Subscribe | |||||||||||||
| 9,586,978 | Anti-viral compounds | ► Subscribe | |||||||||||||
| 8,025,899 | Solid pharmaceutical dosage form | ► Subscribe | |||||||||||||
| 9,023,878 | 2-iminobiotin formulations and uses thereof | ► Subscribe | |||||||||||||
| 8,937,150 | Anti-viral compounds | ► Subscribe | |||||||||||||
| 8,691,878 | Solid pharmaceutical dosage form | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norway | 2015011 | ► Subscribe | |||||||||||||
| Denmark | 2576546 | ► Subscribe | |||||||||||||
| Ukraine | 61096 | ► Subscribe | |||||||||||||
| Taiwan | 201247648 | ► Subscribe | |||||||||||||
| Malaysia | 155645 | ► Subscribe | |||||||||||||
| Hong Kong | 1053783 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 2011156578 | ► Subscribe | |||||||||||||
| New Zealand | 604498 | ► Subscribe | |||||||||||||
| Canada | 2851104 | ► Subscribe | |||||||||||||
| Austria | 514002 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2203431/01 | Switzerland | ► Subscribe | BEI DER ANMELDUNG WURDE DER INHABER IRRTUEMLICH DOPPELT ERFASST. | ||||||||||||
| 668 | Luxembourg | ► Subscribe | PRODUCT NAME: OMBITASVIR, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX R); FIRST REGISTRATION DATE: 20150119 | ||||||||||||
| /2015 | Austria | ► Subscribe | PRODUCT NAME: DASABUVIR ODER EIN SALZ DAVON, EINSCHLIESSLICH DASABUVIR-NATRIUM-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/14/983 20150115 | ||||||||||||
| 0150015 00143 | Estonia | ► Subscribe | PRODUCT NAME: DASABUVIIR;REG NO/DATE: EU/1/14/983 19.01.2015 | ||||||||||||
| C/GB01/044 | United Kingdom | ► Subscribe | PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320 | ||||||||||||
| 2015012,C2368890 | Lithuania | ► Subscribe | PRODUCT NAME: OMBITASVIRAS; REGISTRATION NO/DATE: EU/1/14/982 20150115 | ||||||||||||
| 2015013,C2203431 | Lithuania | ► Subscribe | PRODUCT NAME: DASABUVIRAS; REGISTRATION NO/DATE: EU/1/14/983 20150115 | ||||||||||||
| 2340029/01 | Switzerland | ► Subscribe | PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014 | ||||||||||||
| C0021 | France | ► Subscribe | PRODUCT NAME: PARITAPREVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119 | ||||||||||||
| 2017 00021 | Denmark | ► Subscribe | PRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138/001-007 20161207 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 23,007 others who get our Drug Patent Expiration Alerts:
